Treatment targeting the PD-1/PD-L1 pathway has demonstrated improvements in response and survival in phase II and phase III clinical trials in oncology including treatment for cervical cancer, lung cancer, and melanoma (Colombo et al., 2021, Mok et al., 2019, Robert et al., 2015, Kwok et al., 2016). The gene discussed is CD274; the disease is melanoma.